| scholarly article | Q13442814 |
| P2093 | author name string | Hong Zhu | |
| Gregory R Hook | |||
| Jin Yu | |||
| Mark S Kindy | |||
| Salim S El-Amouri | |||
| Vivian Hook | |||
| P2860 | cites work | Cell-specific expression of beta-amyloid precursor protein isoform mRNAs and proteins in neurons and astrocytes | Q48672944 |
| Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog, polar bear and five other mammals by cross-species polymerase chain reaction analysis | Q48704603 | ||
| Differential splicing of Alzheimer's disease amyloid A4 precursor RNA in rat tissues: PreA4(695) mRNA is predominantly produced in rat and human brain | Q49100289 | ||
| BACE1 gene deletion: impact on behavioral function in a model of Alzheimer's disease. | Q51906403 | ||
| Quantitative changes in the amyloid βA4 precursor protein in Alzheimer cerebrospinal fluid | Q53181168 | ||
| Alzheimer's disease | Q79264357 | ||
| Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein | Q22251280 | ||
| Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain | Q28137790 | ||
| BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics | Q28201876 | ||
| The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity | Q28238581 | ||
| Cysteine protease inhibitors reduce brain beta-amyloid and beta-secretase activity in vivo and are potential Alzheimer's disease therapeutics | Q28240590 | ||
| Genetic cathepsin B deficiency reduces beta-amyloid in transgenic mice expressing human wild-type amyloid precursor protein | Q28247574 | ||
| Inhibitors of cathepsin B improve memory and reduce beta-amyloid in transgenic Alzheimer disease mice expressing the wild-type, but not the Swedish mutant, beta-secretase site of the amyloid precursor protein | Q28264162 | ||
| Inhibition of cathepsin B reduces beta-amyloid production in regulated secretory vesicles of neuronal chromaffin cells: evidence for cathepsin B as a candidate beta-secretase of Alzheimer's disease | Q28272351 | ||
| Cysteine protease inhibitors effectively reduce in vivo levels of brain beta-amyloid related to Alzheimer's disease | Q28285644 | ||
| Cathepsins B and L differentially regulate amyloid precursor protein processing | Q28303285 | ||
| Alzheimer's disease | Q29616743 | ||
| BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. | Q30483997 | ||
| Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation | Q32063777 | ||
| BACE1 is the major beta-secretase for generation of Abeta peptides by neurons | Q32063781 | ||
| BACE1: the beta-secretase enzyme in Alzheimer's disease | Q33202614 | ||
| Genetically altered transgenic models of Alzheimer's disease. | Q34015571 | ||
| Partial reduction of BACE1 improves synaptic plasticity, recent and remote memories in Alzheimer's disease transgenic mice | Q34067152 | ||
| Probing the biology of Alzheimer's disease in mice | Q34206962 | ||
| Guinea pigs as a nontransgenic model for APP processing in vitro and in vivo | Q35098538 | ||
| beta-site amyloid precursor protein cleaving enzyme 1 increases amyloid deposition in brain parenchyma but reduces cerebrovascular amyloid angiopathy in aging BACE x APP[V717I] double-transgenic mice | Q35103410 | ||
| Does my mouse have Alzheimer's disease? | Q35186500 | ||
| Involvement of beta-site APP cleaving enzyme 1 (BACE1) in amyloid precursor protein-mediated enhancement of memory and activity-dependent synaptic plasticity. | Q35768842 | ||
| The Alzheimer's disease beta-secretase enzyme, BACE1. | Q36397690 | ||
| Neprilysin: an enzyme candidate to slow the progression of Alzheimer's disease | Q36579852 | ||
| Beta-site amyloid precursor protein-cleaving enzyme-1 (BACE1)-mediated changes of endogenous amyloid beta in wild-type and transgenic mice in vivo | Q36649496 | ||
| Molecular genetics of Alzheimer's disease: an update | Q37209771 | ||
| Pharmacogenetic features of cathepsin B inhibitors that improve memory deficit and reduce beta-amyloid related to Alzheimer's disease | Q37763948 | ||
| Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease | Q40230652 | ||
| Mutant genes in familial Alzheimer's disease and transgenic models | Q41733323 | ||
| BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease | Q44722202 | ||
| The Swedish APP mutation alters the effect of genetically reduced BACE1 expression on the APP processing. | Q45901500 | ||
| Relation of neuronal APP-751/APP-695 mRNA ratio and neuritic plaque density in Alzheimer's disease | Q46121331 | ||
| Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP Transgenic Mice | Q46143430 | ||
| Levels and alternative splicing of amyloid beta protein precursor (APP) transcripts in brains of APP transgenic mice and humans with Alzheimer's disease | Q48069116 | ||
| BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice | Q48379491 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| P304 | page(s) | 827-840 | |
| P577 | publication date | 2012-01-01 | |
| P1433 | published in | Journal of Alzheimer's Disease | Q6294755 |
| P1476 | title | Deletion of the cathepsin B gene improves memory deficits in a transgenic ALZHeimer's disease mouse model expressing AβPP containing the wild-type β-secretase site sequence | |
| P478 | volume | 29 |
| Q38731927 | Actin dynamics and cofilin-actin rods in alzheimer disease |
| Q41348866 | Aβ42-mediated proteasome inhibition and associated tau pathology in hippocampus are governed by a lysosomal response involving cathepsin B: Evidence for protective crosstalk between protein clearance pathways. |
| Q37346926 | Beta-amyloid peptides undergo regulated co-secretion with neuropeptide and catecholamine neurotransmitters |
| Q28235248 | Brain pyroglutamate amyloid-β is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic |
| Q40410864 | Cathepsin B Improves ß-Amyloidosis and Learning and Memory in Models of Alzheimer's Disease. |
| Q26782938 | Cathepsin B is a New Drug Target for Traumatic Brain Injury Therapeutics: Evidence for E64d as a Promising Lead Drug Candidate |
| Q49357611 | Cathepsin B links oxidative stress to the activation of NLRP3 inflammasome |
| Q38162775 | Cysteine cathepsins in neurological disorders |
| Q36599238 | Cysteine protease cathepsins and matrix metalloproteinases in the development of abdominal aortic aneurysms. |
| Q50472537 | Differential role of calpain-dependent protein cleavage in intermediate and long-term operant memory in Aplysia. |
| Q61814461 | Increased expression and altered subcellular distribution of cathepsin B in microglia induce cognitive impairment through oxidative stress and inflammatory response in mice |
| Q38780921 | Insulin-Like Growth Factor-II/Cation-Independent Mannose 6-Phosphate Receptor in Neurodegenerative Diseases. |
| Q36259524 | Interacting partners of macrophage-secreted cathepsin B contribute to HIV-induced neuronal apoptosis. |
| Q64231716 | Killing Two Angry Birds with One Stone: Autophagy Activation by Inhibiting Calpains in Neurodegenerative Diseases and Beyond |
| Q57172780 | Lysosomal Cathepsin Protease Gene Expression Profiles in the Human Brain During Normal Development |
| Q27024355 | Macrophage derived cystatin B/cathepsin B in HIV replication and neuropathogenesis |
| Q90175392 | Microglial cathepsin B as a key driver of inflammatory brain diseases and brain aging |
| Q40107495 | Microwave & magnetic proteomics of macrophages from patients with HIV-associated cognitive impairment |
| Q35171676 | Overexpression of the IGF-II/M6P receptor in mouse fibroblast cell lines differentially alters expression profiles of genes involved in Alzheimer's disease-related pathology |
| Q34076284 | Pyroglutamate-amyloid-β and glutaminyl cyclase are colocalized with amyloid-β in secretory vesicles and undergo activity-dependent, regulated secretion |
| Q59337000 | Role of the NLRP3 inflammasome in cancer |
| Q37261006 | The MTHFR 677T allele may influence the severity and biochemical risk factors of Alzheimer's disease in an Egyptian population |
| Q39095782 | The Metalloprotease Meprin β Is an Alternative β-Secretase of APP. |
| Q24601910 | The cysteine protease cathepsin B is a key drug target and cysteine protease inhibitors are potential therapeutics for traumatic brain injury |
| Q58716101 | The diverse roles of cysteine proteases in parasites and their suitability as drug targets |
Search more.